Good Medicine Is Not Enough for Longevity Clinics

The clinic that outperforms you might not have better protocols. That's the uncomfortable reality in longevity medicine right now. The science is becoming commoditised quickly. The difference between good and great protocols is shrinking, while the importance of tracking numbers is growing. Physician-owners tend to obsess over the medicine. Understandable, it's what they trained for. But most of them can't tell you their CAC by channel, their LTV to CAC ratio, what their churn looks like, or where exactly their hybrid model stalls. And it does stall, usually somewhere around 70 to 80 patients, because the physician is still the bottleneck for almost everything. The boutique model works until the founder burns out or wants to grow. The scalable model only works if the physician becomes a trust layer rather than a daily dependency. The middle path is where most clinics live and where most of them get stuck. Getting stuck there usually isn't a medicine problem. It's often a churn problem, a staff cost problem, or an uncalculated breakeven number. Sometimes it's an acquisition cost quietly eating the margin. Good medicine is essential, but operations determine if the clinic lasts. The competitor who wins might not have better science; they might just know their numbers.